Back to Journals » International Journal of Nanomedicine » Volume 6

Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice

Authors Bahraini D, Shokri, Samiei A, Kamali-Sarvestani E, Baezegar-Jalali M, Mohammadi-Samani S

Published 20 April 2011 Volume 2011:6 Pages 835—842

DOI https://doi.org/10.2147/IJN.S16805

Review by Single-blind

Peer reviewer comments 3


Mohammad Ali Danesh-Bahreini1,5, Javad Shokri1,2, Afshin Samiei3, Eskandar Kamali-Sarvestani4, Mohammad Barzegar-Jalali1, Soliman Mohammadi-Samani4
1Department of Pharmaceutics, 2Research Center for Pharmaceutical Nanotechnology, School of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran; 3Autoimmune Diseases Research Center, School of Medicine, 4Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Science, Shiraz, Iran; 5Research and Development Department, Exir Pharmaceutical Company, Borujerd, Iran

Background: Leishmaniasis is a protozoan disease, affecting 12 million people in different regions of the world with a wide spectrum of diseases. Although several chemotherapeutic agents have been used for treating the disease, long-term therapy, limited efficacy and the development of drug-resistant parasites remain the major limitations.
Methods: To develop a new nanovaccine for leishmaniasis, recombinant Leishmania superoxide dismutase (SODB1) was loaded onto chitosan nanoparticles by the ionotropic gelation method. Size and loading efficiency of the nanoparticles were evaluated and optimized, and an immunization study was undertaken on BALB/c mice. The mice received phosphate buffer saline (PBS), superoxide dismutase B1 (SODB1) in PBS and nanoparticles via subcutaneous injection. Soluble Leishmania Antigens (SLA) and complete Freund’s adjuvant (CFA) were also injected subcutaneously three times every three weeks (some groups received only a single dose). Three weeks after the last injection, blood samples were collected and assessed with ELISA to detect IgG2a and IgG1.
Results: Immunological analysis showed that in single and triple doses of SODB1 nanoparticles, IgG2a and IgG2a/IgG1 were significantly higher than the other groups (P<0.05).
Conclusion: The results revealed that formulations of SODB1 in biodegradable and stable chitosan nanoparticles can increase the immunogenicity toward cell-mediated immunity (TH1 cells producing IgG2a in mice) that is effective in Leishmania eradication and could be presented as a single dose nanovaccine for leishmaniasis.

Keywords: chitosan nanoparticles, leishmaniasis, vaccine, superoxide dismutase

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]